
    
      This study will be carried out on 100 patients with liver cirrhosis and ascites who will be
      enrolled from Tanta University, Tropical Medicine Department in the period between January
      2014 to 6 months. The selected patients will be randomly assigned to receive 400 mg of
      norfloxacin daily or 1200 mg of rifaximin daily and will be classified into two groups :

      Group 1 : 50 patients will be treated with 1200 mg of rifaximin daily. Group 2 : 50 patients
      will be treated with 400 mg of norfloxacin daily.
    
  